Company earnings numbers are typically highly analyzed by investors and analysts alike. Earnings are important because they can provide insight into a company’s profitability. Sell-side Street analysts are expecting ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) to post quarterly EPS of $-0.14. The company is next scheduled to release earnings on or around 2017-02-10 for the period ending 2016-12-31.
Before and after the earnings report, covering Wall Street analysts often make updates to their projections. Analysts taken into consideration by Zacks Research have a current mean target price of $4.5 on shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV). This target consists of 2 research analysts polled by Zacks Research. Analysts may have different stances on where they see the stock headed in the future.
Among the polled analysts, the highest estimate sees the stock going to 5 in the next year. The analyst with the lowest target price views shares reaching $4 within the same period. In looking at the standard deviation of all estimates, we arrive at 0.707. Zacks Research also compiles analyst ratings using a scale that ranges from 1 to 5. If the company has a ratings score of 1, this would represent a Strong Buy. If the company has a 5 rating, this would signify a Strong Sell. Combining all the ratings on ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), the current mean stands at 1. Breaking those down we see that the ratings are as follows: 2 Strong Buy, 0 Rated Buy, 0 Rated Hold and 0 Rated Sell.
Want to receive stock recommendations on ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) as well as the latest stock picks before the Street? Sign up below!
Analyst recommendations and estimates are for informational purposes only and should be used along with a number of other factors when considering an investment position. Part of the data in this report is derived from Zacks Research and FactSet. Ratings and estimates change daily and thus the numbers may differ slightly if a new report has been issued within the last 24-hours. The consensus numbers take into account the reports from over 160 brokerage firms. The job of analysts is to issue recommendations for their clients, and not typically for the general public. Analyst forecasts, earnings estimates and price target projections are issued to help their clients make money through stock investments. We in no way are suggesting that readers make any decision on ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) based on the information in this report.